A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI: Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial

Thrombosis and Haemostasis

Volumn 117, Issue 1, 2017, Pages 188-195

  Sibbing, Dirk ^a,b   Aradi, Dániel ^c   Jacobshagen, Claudius ^d   Gross, Lisa ^a   Trenk, Dietmar ^e   Geisler, Tobias ^f   Orban, Martin ^a   Gori, Tommaso ^g   Hadamitzky, Martin ^h   Merkely, Béla ⁱ   Kiss, Róbert Gábor ^j   Komócsi, András ^k   Dézsi, Csaba A ^l   Thalmeier, Andreas ^a   Löw, Anja ^a   Holdt, Lesca ^a   Teupser, Daniel ^a   Ince, Hüseyin ^m   Felix, Stephan B ^b,n   Parma, Radoslaw ^o   Malek, Lukasz ^p   Horstkotte, Jan ^q   Baylacher, Monika ^a   Schwinger, Robert ^r   Rieber, Johannes ^a,s   Mudra, Harald ^t   Hausleiter, Jörg ^a,b   Huber, Kurt ^u   Neumann, Franz Josef ^e   Koltowski, Lukasz ^v   Huczek, Zenon ^v   Mehilli, Julinda ^a,b   Massberg, Steffen ^a,b   more..

^a UNIVERSITY OF MUNICH   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ University of Semmelweis   (Hungary)

^j Military Hospital National Health Center   (Hungary)

^k UNIVERSITY OF PÉCS   (Hungary)

^l Petz Aladár County Teaching Hospital   (Hungary)

^m ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

ⁿ UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^o MEDICAL UNIVERSITY OF SILESIA   (Poland)

^p INSTITUTE OF CARDIOLOGY   (Poland)

^q Heart Center Siegburg   (Germany)

^r Kliniken Nordoberpfalz AG   (Germany)

^s Munich Heart Alliance   (Germany)

^t Klinikum Neuperlach   (Germany)

^u MEDICAL UNIVERSITY OF VIENNA   (Austria)

^v MEDICAL UNIVERSITY OF WARSAW   (Poland)

more..

Author keywords

Acute coronary syndrome; Antiplatelet drugs; Platelets

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; RIVAROXABAN; TICAGRELOR; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; COMORBIDITY; CONTROLLED STUDY; FOLLOW UP; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STENT THROMBOSIS; VEIN PUNCTURE; ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; EUROPE; FEMALE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; THROMBOCYTE; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ACUTE CORONARY SYNDROME; ADULT; AGED; BLOOD PLATELETS; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; EUROPE; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RESEARCH DESIGN; RISK FACTORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85007357335     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-07-0557     Document Type: Article

References (42)

1. Fitzgerald DJ, Roy L, Catella F, et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989.
2. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267-315.
3. Authors/Task Force, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularisation: The Task Force on Myocardial Revascularisation of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-619.
4. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-93.
5. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
6. Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb Haemost 2009; 102: 7-14.
7. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischaemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
8. Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 36: 1762-1771.
9. Gurbel PA, Erlinge D, Ohman EM, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularisation: the TRILOGY ACS platelet function substudy. J Am Med Assoc 2012; 308: 1785-1794.
10. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loadingand maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
11. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
12. Larmore C, Effron MB, Molife C, et al. "Real-World" comparison of prasugrel with ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention in the United States. Catheter Cardiovasc Interv 2015; Epub ahead of print.
13. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382: 614-623.
14. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimising Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51: 2028-2033.
15. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800.
16. Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularisation: results from the PLATO trial. Eur Heart J 2014; 35: 2083-2093.
17. Aradi D, Komocsi A, Price MJ, et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. Int J Cardiol 2013; 167: 2140-2148.
18. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomised trial. J Am Med Assoc 2011; 305: 1097-1105.
19. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
20. Trenk D, Stone GW, Gawaz M, et al. A Randomised Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J Am Coll Cardiol 2012; 59: 2159-2164.
21. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569-2619.
22. Sibbing D, Braun S, Jawansky S, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99: 121-126.
23. Czarny MJ, Nathan AS, Yeh RW, et al. Adherence to dual antiplatelet therapy after coronary stenting: a systematic review. Clin Cardiol 2014; 37: 505-513.
24. Cutlip DE, Kereiakes DJ, Mauri L, et al. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. JACC Cardiovasc Interv 2015; 8: 404-410.
25. Straub N, Beivers A, Lenk E, et al. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients. Thromb Haemost 2014; 111: 290-299.
26. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551-2567.
27. Mehran R, Rao SV, Bhatt DL, et al. Standardised bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736-2747.
28. Ndrepepa G, Schuster T, Hadamitzky M, et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 2012; 125: 1424-1431.
29. Cutlip DE, Windecker S, Mehran R, et al. Clinical endpoints in coronary stent trials: a case for standardised definitions. Circulation 2007; 115: 2344-2351.
30. Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 2016; 13: 11-27.
31. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
32. Siller-Matula JM, Christ G, Lang IM, et al. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010; 8: 351-359.
33. Sibbing D, Byrne RA, Bernlochner I, et al. High platelet reactivity and clinical outcome - Fact and fiction. Thromb Haemost 2011; 106: 191-202.
34. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
35. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
36. Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J 2014; 78: 1684-1692.
37. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple endpoint. J Am Coll Cardiol 2008; 51: 690-697.
38. Schulz S, Angiolillo DJ, Antoniucci D, et al. Randomised comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISARREACT) 5 trial. J Cardiovasc Transl Res 2014; 7: 91-100.
39. Bergmeijer TO, Janssen PW, Schipper JC, et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Am Heart J 2014; 168: 16-22 e1.
40. Povsic TJ, Roe MT, Ohman EM, et al. A randomised trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. Am Heart J 2016; 174: 120-128.
41. Vranckx P, Valgimigli M, Windecker S, et al. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention 2015; Epub ahead of print.
42. Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomised antarctic study. Am Heart J 2014; 168: 674-681.